PREV_PKDL: ImmStat@Cure multidimensional, multiparameter phenotyping study begun in Kenya
The multidimensional, multiparameter phenotyping study (ImmStat@Cure, NCT04342715) within the PREV_PKDL project kicked-off in April 2022. This study aims at understanding the pathogenesis of post kala azar dermal leishmaniasis (PKDL) – and the underlying immune mechanism – in patients treated for visceral leishmaniasis (VL). ImmStat@Cure is designed as a multicentre study across four endemic East African countries: Ethiopia, Kenya, Sudan and Uganda. Following a pre-initiation hands-on training at the field site in Kimalel Sub-County, the first cohort volunteer has been enrolled at the Kenya Medical Research Institute (KEMRI, Kenya).